$CHRS
Coherus BioSciences Inc

2023 Q2 Form 10-Q Financial Statement

#000155837023008529 Filed on May 08, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $58.72M $32.44M $60.12M
YoY Change -2.47% -46.04% -27.6%
Cost Of Revenue $24.85M $16.87M $9.370M
YoY Change 120.34% 80.09% 24.75%
Gross Profit $33.87M $15.56M $50.75M
YoY Change -30.77% -69.33% -32.81%
Gross Profit Margin 57.68% 47.98% 84.41%
Selling, General & Admin $45.14M $49.15M $48.75M
YoY Change -11.96% 0.82% 23.77%
% of Gross Profit 133.29% 315.85% 96.07%
Research & Development $23.27M $34.15M $82.92M
YoY Change -44.08% -58.81% -59.25%
% of Gross Profit 68.7% 219.47% 163.4%
Depreciation & Amortization $800.0K $949.0K $767.0K
YoY Change -9.81% 23.73% -4.13%
% of Gross Profit 2.36% 6.1% 1.51%
Operating Expenses $68.41M $83.31M $131.7M
YoY Change -26.35% -36.73% -45.79%
Operating Profit -$34.54M -$67.75M -$80.93M
YoY Change -21.52% -16.29% -51.65%
Interest Expense $9.943M $9.712M $8.969M
YoY Change 51.11% 8.28% 58.8%
% of Operating Profit
Other Income/Expense, Net $1.617M $1.728M $32.00K
YoY Change 265.01% 5300.0% -47.54%
Pretax Income -$42.87M -$75.73M -$96.08M
YoY Change -14.52% -21.18% -44.44%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$42.87M -$75.73M -$96.08M
YoY Change -14.52% -21.18% -44.44%
Net Earnings / Revenue -73.01% -233.47% -159.83%
Basic Earnings Per Share -$0.49 -$0.96 -$1.24
Diluted Earnings Per Share -$0.49 -$0.96 -$1.24
COMMON SHARES
Basic Shares Outstanding 80.55M 79.61M 77.25M
Diluted Shares Outstanding 87.27M 79.27M 77.25M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $144.7M $128.1M $325.7M
YoY Change -47.47% -60.67% -18.48%
Cash & Equivalents $72.92M $16.15M $325.7M
Short-Term Investments $71.79M $111.9M $0.00
Other Short-Term Assets $35.48M $36.97M $32.78M
YoY Change 48.77% 12.79% 27.54%
Inventory $63.99M $49.41M $36.95M
Prepaid Expenses
Receivables $141.3M $101.5M $117.0M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $385.5M $315.9M $512.4M
YoY Change -13.72% -38.35% -16.98%
LONG-TERM ASSETS
Property, Plant & Equipment $6.929M $7.724M $7.998M
YoY Change -27.47% -3.43% -58.13%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $7.523M $7.825M $9.956M
YoY Change -25.87% -21.4% -6.95%
Total Long-Term Assets $84.11M $86.50M $80.94M
YoY Change -15.23% 6.86% 6.45%
TOTAL ASSETS
Total Short-Term Assets $385.5M $315.9M $512.4M
Total Long-Term Assets $84.11M $86.50M $80.94M
Total Assets $469.6M $402.4M $593.4M
YoY Change -13.99% -32.18% -14.41%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $29.28M $23.23M $21.09M
YoY Change 67.44% 10.14% 36.24%
Accrued Expenses $41.81M $32.06M $45.89M
YoY Change 0.05% -30.15% 2.35%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $169.4M $123.4M $153.7M
YoY Change 20.38% -19.73% -40.32%
LONG-TERM LIABILITIES
Long-Term Debt $472.2M $471.6M $420.5M
YoY Change 12.17% 12.17% 40.67%
Other Long-Term Liabilities $102.0K $102.0K $102.0K
YoY Change 0.0% 0.0% -86.4%
Total Long-Term Liabilities $102.0K $102.0K $102.0K
YoY Change 0.0% 0.0% -86.4%
TOTAL LIABILITIES
Total Short-Term Liabilities $169.4M $123.4M $153.7M
Total Long-Term Liabilities $102.0K $102.0K $102.0K
Total Liabilities $644.4M $598.9M $580.8M
YoY Change 13.32% 3.12% 2.69%
SHAREHOLDERS EQUITY
Retained Earnings -$1.460B -$1.417B -$1.146B
YoY Change 22.08% 23.68% 22.47%
Common Stock $9.000K $8.000K $7.000K
YoY Change 28.57% 14.29% 0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$174.8M -$196.5M $12.56M
YoY Change
Total Liabilities & Shareholders Equity $469.6M $402.4M $593.4M
YoY Change -13.99% -32.18% -14.41%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$42.87M -$75.73M -$96.08M
YoY Change -14.52% -21.18% -44.44%
Depreciation, Depletion And Amortization $800.0K $949.0K $767.0K
YoY Change -9.81% 23.73% -4.13%
Cash From Operating Activities -$38.92M -$68.73M -$54.05M
YoY Change -22.23% 27.18% -4053.55%
INVESTING ACTIVITIES
Capital Expenditures $100.0K $152.0K $615.0K
YoY Change -111.36% -75.28% 324.14%
Acquisitions
YoY Change
Other Investing Activities $41.47M $17.68M -$35.00M
YoY Change -150.51% -87.73%
Cash From Investing Activities $41.36M $17.53M -$35.62M
YoY Change -4800.57% -149.21% -87.52%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 54.32M 3.804M -1.855M
YoY Change 7434.67% -305.07% -176.06%
NET CHANGE
Cash From Operating Activities -38.92M -68.73M -54.05M
Cash From Investing Activities 41.36M 17.53M -35.62M
Cash From Financing Activities 54.32M 3.804M -1.855M
Net Change In Cash 56.77M -47.40M -91.52M
YoY Change -213.11% -48.2% -67.51%
FREE CASH FLOW
Cash From Operating Activities -$38.92M -$68.73M -$54.05M
Capital Expenditures $100.0K $152.0K $615.0K
Free Cash Flow -$39.02M -$68.88M -$54.66M
YoY Change -20.63% 26.02% -4573.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2023Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2022Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001512762
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 chrs Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2022Q4 chrs Fair Value Assets Level2 To Level1 Transfers Amount1
FairValueAssetsLevel2ToLevel1TransfersAmount1
0
CY2023Q1 chrs Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2022Q4 chrs Fair Value Liabilities Level1 To Level2 Transfers Amount1
FairValueLiabilitiesLevel1ToLevel2TransfersAmount1
0
CY2023Q1 chrs Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2022Q4 chrs Fair Value Liabilities Level2 To Level1 Transfers Amount1
FairValueLiabilitiesLevel2ToLevel1TransfersAmount1
0
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Liability Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityTransfersNet
0
CY2023Q1 chrs Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q4 chrs Fair Value Assets Level1 To Level2 Transfers Amount1
FairValueAssetsLevel1ToLevel2TransfersAmount1
0
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
78851516
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
80488296
CY2023Q1 dei Document Type
DocumentType
10-Q
CY2023Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2023Q1 dei Document Period End Date
DocumentPeriodEndDate
2023-03-31
CY2023Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2023Q1 dei Entity File Number
EntityFileNumber
001-36721
CY2023Q1 dei Entity Registrant Name
EntityRegistrantName
Coherus BioSciences, Inc.
CY2023Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2023Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-3615821
CY2023Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
333 Twin Dolphin Drive
CY2023Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 600
CY2023Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
Redwood City
CY2023Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2023Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94065
CY2023Q1 dei City Area Code
CityAreaCode
650
CY2023Q1 dei Local Phone Number
LocalPhoneNumber
649-3530
CY2023Q1 dei Security12b Title
Security12bTitle
Common Stock, $0.0001 par value per share
CY2023Q1 dei Trading Symbol
TradingSymbol
CHRS
CY2023Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2023Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2023Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2023Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2023Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2023Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2023Q1 dei Entity Shell Company
EntityShellCompany
false
CY2023Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
80553730
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16145000
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63547000
CY2023Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
111944000
CY2022Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
128134000
CY2023Q1 us-gaap Receivables Net Current
ReceivablesNetCurrent
101458000
CY2022Q4 us-gaap Receivables Net Current
ReceivablesNetCurrent
109964000
CY2023Q1 us-gaap Inventory Net
InventoryNet
49406000
CY2022Q4 us-gaap Inventory Net
InventoryNet
38791000
CY2023Q1 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
16019000
CY2022Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
17880000
CY2023Q1 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
20954000
CY2022Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
22918000
CY2023Q1 us-gaap Assets Current
AssetsCurrent
315926000
CY2022Q4 us-gaap Assets Current
AssetsCurrent
381234000
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
7724000
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
8754000
CY2023Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
65081000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
76260000
CY2023Q1 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
5870000
CY2022Q4 us-gaap Intangible Assets Net Including Goodwill
IntangibleAssetsNetIncludingGoodwill
5931000
CY2023Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
7825000
CY2022Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
8668000
CY2023Q1 us-gaap Assets
Assets
402426000
CY2022Q4 us-gaap Assets
Assets
480847000
CY2023Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
23231000
CY2022Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
11526000
CY2023Q1 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
55697000
CY2022Q4 chrs Accrued Rebates Fees And Reserve Current
AccruedRebatesFeesAndReserveCurrent
54461000
CY2023Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
12422000
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
22610000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32057000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
50097000
CY2023Q1 us-gaap Liabilities Current
LiabilitiesCurrent
123407000
CY2022Q4 us-gaap Liabilities Current
LiabilitiesCurrent
138694000
CY2023Q1 chrs Term Loans Payable Noncurrent
TermLoansPayableNoncurrent
245718000
CY2022Q4 chrs Term Loans Payable Noncurrent
TermLoansPayableNoncurrent
245483000
CY2023Q1 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
225900000
CY2022Q4 us-gaap Convertible Subordinated Debt Noncurrent
ConvertibleSubordinatedDebtNoncurrent
225575000
CY2023Q1 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
3806000
CY2022Q4 chrs Operating And Finance Lease Liability Noncurrent
OperatingAndFinanceLeaseLiabilityNoncurrent
5046000
CY2023Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
102000
CY2022Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
3467000
CY2023Q1 us-gaap Liabilities
Liabilities
598933000
CY2022Q4 us-gaap Liabilities
Liabilities
618265000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
80488296
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
78851516
CY2023Q1 us-gaap Common Stock Value
CommonStockValue
8000
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
8000
CY2023Q1 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1221100000
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
1204431000
CY2023Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-278000
CY2022Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-249000
CY2023Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1417337000
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-1341608000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-196507000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-137418000
CY2023Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
402426000
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
480847000
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
32436000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
60115000
CY2023Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
16874000
CY2022Q1 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
9370000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
34154000
CY2022Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
82917000
CY2023Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
49153000
CY2022Q1 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
48753000
CY2023Q1 us-gaap Costs And Expenses
CostsAndExpenses
100181000
CY2022Q1 us-gaap Costs And Expenses
CostsAndExpenses
141040000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-67745000
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-80925000
CY2023Q1 us-gaap Interest Expense
InterestExpense
9712000
CY2022Q1 us-gaap Interest Expense
InterestExpense
8969000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6222000
CY2023Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1728000
CY2022Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
32000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-75729000
CY2022Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-96084000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-75729000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-96084000
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.96
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.96
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.24
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.24
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
79268853
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
79268853
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
77253699
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
77253699
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-75729000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-96084000
CY2023Q1 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-29000
CY2022Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-2000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-75758000
CY2022Q1 us-gaap Comprehensive Income Net Of Tax Including Portion Attributable To Noncontrolling Interest
ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
-96086000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
-137418000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-75729000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
103000
CY2023Q1 us-gaap Stock Issued During Period Value Purchase Of Assets
StockIssuedDuringPeriodValuePurchaseOfAssets
7059000
CY2023Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2781000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12288000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-29000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
-196507000
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
97726000
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-96084000
CY2022Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
544000
CY2022Q1 us-gaap Adjustments Related To Tax Withholding For Share Based Compensation
AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation
2658000
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
13037000
CY2022Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-2000
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
12563000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-75729000
CY2022Q1 us-gaap Profit Loss
ProfitLoss
-96084000
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
949000
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
767000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
12282000
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
12879000
CY2023Q1 us-gaap Inventory Write Down
InventoryWriteDown
3241000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1339000
CY2023Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
656000
CY2022Q1 us-gaap Amortization Of Debt Discount Premium
AmortizationOfDebtDiscountPremium
3696000
CY2022Q1 chrs Upfront License Fee Payments Related To License And Collaboration Arrangements
UpfrontLicenseFeePaymentsRelatedToLicenseAndCollaborationArrangements
35000000
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6222000
CY2023Q1 chrs Other Noncash Adjustments
OtherNoncashAdjustments
554000
CY2022Q1 chrs Other Noncash Adjustments
OtherNoncashAdjustments
592000
CY2023Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-8529000
CY2022Q1 us-gaap Increase Decrease In Receivables
IncreaseDecreaseInReceivables
-5991000
CY2023Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2671000
CY2022Q1 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
2962000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1861000
CY2022Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-248000
CY2023Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-2057000
CY2022Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
7632000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
11739000
CY2022Q1 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
4757000
CY2023Q1 chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
1236000
CY2022Q1 chrs Increase Decrease In Accrued Rebates Fees And Reserve
IncreaseDecreaseInAccruedRebatesFeesAndReserve
-7133000
CY2023Q1 chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-10188000
CY2022Q1 chrs Increase Decrease In Accrued Compensation
IncreaseDecreaseInAccruedCompensation
-7144000
CY2023Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-21909000
CY2022Q1 us-gaap Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
-3242000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-68732000
CY2022Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-54045000
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
152000
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
615000
CY2023Q1 us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
178000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
17500000
CY2022Q1 chrs Upfront And Milestone Based License Fee Payments Investing Activities
UpfrontAndMilestoneBasedLicenseFeePaymentsInvestingActivities
35000000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
17526000
CY2022Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-35615000
CY2022Q1 us-gaap Proceeds From Issuance Of Debt
ProceedsFromIssuanceOfDebt
191190000
CY2023Q1 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
6835000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
103000
CY2022Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
544000
CY2023Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2781000
CY2022Q1 us-gaap Payments Related To Tax Withholding For Share Based Compensation
PaymentsRelatedToTaxWithholdingForShareBasedCompensation
2658000
CY2022Q1 us-gaap Repayments Of Convertible Debt
RepaymentsOfConvertibleDebt
109000000
CY2022Q1 us-gaap Repayments Of Debt
RepaymentsOfDebt
81750000
CY2023Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-353000
CY2022Q1 us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-181000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
3804000
CY2022Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1855000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-47402000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-91515000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63987000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
417635000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16585000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
326120000
CY2023Q1 chrs Product Pipeline Number Of Drug Candidates
ProductPipelineNumberOfDrugCandidates
3
CY2023Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Use of Estimates</p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:10pt;text-align:justify;text-indent:24.5pt;margin:0pt 0pt 12pt 0pt;">The preparation of financial statements in conformity with U.S. GAAP requires management to make judgements, estimates and assumptions that affect the reported amounts of assets, liabilities, revenue and expenses, and related disclosures. Management bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances. These estimates form the basis for making judgments about the carrying values of assets and liabilities when these values are not readily apparent from other sources. Estimates are assessed each period and updated to reflect current information. Accounting estimates and judgements are inherently uncertain and therefore actual results could differ from these estimates.</p>
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
63547000
CY2021Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
417195000
CY2022Q4 us-gaap Restricted Cash
RestrictedCash
440000
CY2021Q4 us-gaap Restricted Cash
RestrictedCash
440000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
63987000
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
417635000
CY2023Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
16145000
CY2022Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
325680000
CY2023Q1 us-gaap Restricted Cash
RestrictedCash
440000
CY2022Q1 us-gaap Restricted Cash
RestrictedCash
440000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16585000
CY2022Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
326120000
CY2023Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
32436000
CY2022Q1 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
60115000
CY2022Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
100503000
CY2023Q1 chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
121509000
CY2023Q1 chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
390000
CY2023Q1 chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
131968000
CY2023Q1 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
90434000
CY2021Q4 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
109723000
CY2022Q1 chrs Reserve For Sales Discounts And Allowances Constitute Variable Consideration
ReserveForSalesDiscountsAndAllowancesConstituteVariableConsideration
146294000
CY2022Q1 chrs Provision Related To Sales Made In Prior Period
ProvisionRelatedToSalesMadeInPriorPeriod
-3146000
CY2022Q1 chrs Payments And Customer Credits Issued From Reserve For Discounts And Allowances Constitute Variable Consideration
PaymentsAndCustomerCreditsIssuedFromReserveForDiscountsAndAllowancesConstituteVariableConsideration
154281000
CY2022Q1 chrs Reserve For Discounts And Allowances Constitute Variable Consideration
ReserveForDiscountsAndAllowancesConstituteVariableConsideration
98590000
CY2023Q1 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2022 us-gaap Fair Value Measurement With Unobservable Inputs Reconciliation Recurring Basis Asset Transfers Net
FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersNet
0
CY2023Q1 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
123663000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
16000
CY2023Q1 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
23000
CY2023Q1 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
123656000
CY2022Q4 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
191623000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
43000
CY2022Q4 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
21000
CY2022Q4 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
191645000
CY2023Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position Number Of Positions
DebtSecuritiesAvailableForSaleUnrealizedLossPositionNumberOfPositions
11
CY2023Q1 us-gaap Impairment Of Intangible Assets Finitelived
ImpairmentOfIntangibleAssetsFinitelived
0
CY2023Q1 chrs Contractual Maturities Of Available For Sale Debt Securities Remaining Maturity
ContractualMaturitiesOfAvailableForSaleDebtSecuritiesRemainingMaturity
P1Y
CY2023Q1 chrs Remaining Contractual Maturities Of Available For Sale Debt Securities Acquisition
RemainingContractualMaturitiesOfAvailableForSaleDebtSecuritiesAcquisition
P8M
CY2022Q1 us-gaap Marketable Securities
MarketableSecurities
0
CY2022Q1 us-gaap Unrealized Gain Loss On Securities
UnrealizedGainLossOnSecurities
0
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
13008000
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
10262000
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
82206000
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
86712000
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
19273000
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
18077000
CY2023Q1 us-gaap Inventory Gross
InventoryGross
114487000
CY2022Q4 us-gaap Inventory Gross
InventoryGross
115051000
CY2023Q1 us-gaap Inventory Net
InventoryNet
49406000
CY2022Q4 us-gaap Inventory Net
InventoryNet
38791000
CY2023Q1 us-gaap Inventory Noncurrent
InventoryNoncurrent
65081000
CY2022Q4 us-gaap Inventory Noncurrent
InventoryNoncurrent
76260000
CY2023Q1 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
114487000
CY2022Q4 chrs Inventory Current And Noncurrent
InventoryCurrentAndNoncurrent
115051000
CY2023Q1 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
16000000.0
CY2023Q1 chrs Prepayments Made To Cmo For Manufacturing Services
PrepaymentsMadeToCmoForManufacturingServices
11600000
CY2023Q1 chrs Prepayments Made To Cmo For Other Research And Development Pipeline Program
PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
4400000
CY2022Q4 chrs Prepaid Manufacturing Expense Current
PrepaidManufacturingExpenseCurrent
17900000
CY2022Q4 chrs Prepayments Made To Cmo For Manufacturing Services
PrepaymentsMadeToCmoForManufacturingServices
13000000.0
CY2022Q4 chrs Prepayments Made To Cmo For Other Research And Development Pipeline Program
PrepaymentsMadeToCmoForOtherResearchAndDevelopmentPipelineProgram
4900000
CY2023Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
28244000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Before Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetBeforeAccumulatedDepreciationAndAmortization
28911000
CY2023Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
20520000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAccumulatedDepreciationAndAmortization
20157000
CY2023Q1 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
7724000
CY2022Q4 us-gaap Property Plant And Equipment And Finance Lease Right Of Use Asset After Accumulated Depreciation And Amortization
PropertyPlantAndEquipmentAndFinanceLeaseRightOfUseAssetAfterAccumulatedDepreciationAndAmortization
8754000
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
900000
CY2022Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
800000
CY2023Q1 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
3200000
CY2022Q4 us-gaap Capitalized Computer Software Net
CapitalizedComputerSoftwareNet
3500000
CY2023Q1 chrs Accrued Commercial And Research And Development Manufacturing Liabilities Current
AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent
9677000
CY2022Q4 chrs Accrued Commercial And Research And Development Manufacturing Liabilities Current
AccruedCommercialAndResearchAndDevelopmentManufacturingLiabilitiesCurrent
21774000
CY2023Q1 chrs Accrued Co Development Costs Payable To Junshi Biosciences
AccruedCoDevelopmentCostsPayableToJunshiBiosciences
3480000
CY2022Q4 chrs Accrued Co Development Costs Payable To Junshi Biosciences
AccruedCoDevelopmentCostsPayableToJunshiBiosciences
8356000
CY2023Q1 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
4436000
CY2022Q4 chrs Lease Liabilities Operating And Financing
LeaseLiabilitiesOperatingAndFinancing
4318000
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
14464000
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
15649000
CY2023Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
32057000
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
50097000
CY2022Q1 chrs Collaboration Agreement Option Exercise Fee Per Program
CollaborationAgreementOptionExerciseFeePerProgram
35000000.0
CY2023Q1 us-gaap Finite Lived Intangible Asset Useful Life
FiniteLivedIntangibleAssetUsefulLife
P10Y
CY2023Q1 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
2500000
CY2022Q4 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
2900000
CY2020Q2 us-gaap Share Price
SharePrice
14.82
CY2023Q1 us-gaap Share Price
SharePrice
6.84
CY2023Q1 us-gaap Purchase Obligation Future Minimum Payments Remainder Of Fiscal Year
PurchaseObligationFutureMinimumPaymentsRemainderOfFiscalYear
34666000
CY2023Q1 us-gaap Purchase Obligation Due In Next Twelve Months
PurchaseObligationDueInNextTwelveMonths
32643000
CY2023Q1 us-gaap Purchase Obligation Due In Second Year
PurchaseObligationDueInSecondYear
4435000
CY2023Q1 us-gaap Purchase Obligation Due In Third Year
PurchaseObligationDueInThirdYear
5469000
CY2023Q1 us-gaap Purchase Obligation Due In Fourth Year
PurchaseObligationDueInFourthYear
5470000
CY2023Q1 us-gaap Purchase Obligation
PurchaseObligation
82683000
CY2022Q2 us-gaap Product Liability Contingency Loss Exposure Not Accrued Best Estimate
ProductLiabilityContingencyLossExposureNotAccruedBestEstimate
14000000.0
CY2023Q1 chrs Number Of Derivative Instrument Held For Trading Or Speculative Purpose
NumberOfDerivativeInstrumentHeldForTradingOrSpeculativePurpose
0
CY2023Q1 us-gaap Gain Loss On Foreign Currency Derivative Instruments Not Designated As Hedging Instruments
GainLossOnForeignCurrencyDerivativeInstrumentsNotDesignatedAsHedgingInstruments
-123000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
38524416
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
40693651

Files In Submission

Name View Source Status
0001558370-23-008529-index-headers.html Edgar Link pending
0001558370-23-008529-index.html Edgar Link pending
0001558370-23-008529.txt Edgar Link pending
0001558370-23-008529-xbrl.zip Edgar Link pending
chrs-20230331.xsd Edgar Link pending
chrs-20230331x10q.htm Edgar Link pending
chrs-20230331xex10d1.htm Edgar Link pending
chrs-20230331xex10d2.htm Edgar Link pending
chrs-20230331xex10d3.htm Edgar Link pending
chrs-20230331xex31d1.htm Edgar Link pending
chrs-20230331xex31d2.htm Edgar Link pending
chrs-20230331xex32d1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
chrs-20230331_cal.xml Edgar Link unprocessable
chrs-20230331_def.xml Edgar Link unprocessable
chrs-20230331_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
chrs-20230331_lab.xml Edgar Link unprocessable
chrs-20230331x10q_htm.xml Edgar Link completed
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending